M&R Capital Management’s Pfizer PFE Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q3 | $935K | Sell |
32,296
-737
| -2% | -$21.5K | 0.21% | 64 |
|
|
2024
Q2 | $924K | Sell |
33,033
-3,521
| -10% | -$96.9K | 0.22% | 62 |
|
|
2024
Q1 | $1.01M | Sell |
36,554
-3,971
| -10% | -$110K | 0.25% | 61 |
|
|
2023
Q4 | $1.17M | Sell |
40,525
-2,972
| -7% | -$89.8K | 0.29% | 53 |
|
|
2023
Q3 | $1.44M | Sell |
43,497
-844
| -2% | -$29.8K | 0.39% | 47 |
|
|
2023
Q2 | $1.63M | Sell |
44,341
-50
| -0.1% | -$1.95K | 0.42% | 44 |
|
|
2023
Q1 | $1.81M | Sell |
44,391
-1,048
| -2% | -$45.3K | 0.51% | 43 |
|
|
2022
Q4 | $2.33M | Sell |
45,439
-313
| -0.7% | -$15K | 0.64% | 40 |
|
|
2022
Q3 | $2M | Buy |
45,752
+76
| +0.2% | +$3.69K | 0.57% | 43 |
|
|
2022
Q2 | $2.39M | Sell |
45,676
-355
| -0.8% | -$18.1K | 0.63% | 39 |
|
|
2022
Q1 | $2.38M | Buy |
46,031
+4,134
| +10% | +$214K | 0.51% | 43 |
|
|
2021
Q4 | $2.47M | Buy |
41,897
+5,230
| +14% | +$259K | 0.51% | 43 |
|
|
2021
Q3 | $1.58M | Buy |
36,667
+200
| +0.5% | +$8.86K | 0.36% | 52 |
|
|
2021
Q2 | $1.43M | Buy |
36,467
+1,644
| +5% | +$63.9K | 0.33% | 56 |
|
|
2021
Q1 | $1.26M | Sell |
34,823
-12,934
| -27% | -$459K | 0.31% | 57 |
|
|
2020
Q4 | $1.76M | Sell |
47,757
-7,482
| -14% | -$274K | 0.4% | 46 |
|
|
2020
Q3 | $1.92M | Buy |
55,239
+106
| +0.2% | +$3.72K | 0.48% | 45 |
|
|
2020
Q2 | $1.71M | Sell |
55,133
-27,061
| -33% | -$919K | 0.46% | 45 |
|
|
2020
Q1 | $2.54M | Sell |
82,194
-32,574
| -28% | -$1.11M | 0.76% | 35 |
|
|
2019
Q4 | $4.26M | Sell |
114,768
-10,779
| -9% | -$384K | 0.96% | 29 |
|
|
2019
Q3 | $4.28M | Sell |
125,547
-5,601
| -4% | -$204K | 0.99% | 30 |
|
|
2019
Q2 | $5.39M | Sell |
131,148
-269
| -0.2% | -$10.7K | 1.22% | 24 |
|
|
2019
Q1 | $4.98M | Buy |
131,417
+7,752
| +6% | +$310K | 1.14% | 28 |
|
|
2018
Q4 | $5.12M | Buy |
123,665
+368
| +0.3% | +$15.3K | 1.34% | 24 |
|
|
2018
Q3 | $5.16M | Sell |
123,297
-508
| -0.4% | -$19.6K | 1.13% | 29 |
|
|
2018
Q2 | $4.26M | Sell |
123,805
-3,038
| -2% | -$104K | 0.98% | 33 |
|
|
2018
Q1 | $4.27M | Sell |
126,843
-879
| -0.7% | -$30.2K | 0.99% | 33 |
|
|
2017
Q4 | $4.39M | Buy |
127,722
+3,722
| +3% | +$127K | 1.02% | 30 |
|
|
2017
Q3 | $4.2M | Sell |
124,000
-2,618
| -2% | -$84.1K | 1.01% | 31 |
|
|
2017
Q2 | $3.99M | Sell |
126,618
-10,324
| -8% | -$326K | 0.99% | 31 |
|
|
2017
Q1 | $4.1M | Buy |
136,942
+10,108
| +8% | +$319K | 1.03% | 31 |
|
|
2016
Q4 | $3.58M | Buy |
126,834
+255
| +0.2% | +$7.79K | 0.97% | 29 |
|
|
2016
Q3 | $3.73M | Buy |
126,579
+7,859
| +7% | +$263K | 1.06% | 29 |
|
|
2016
Q2 | $3.61M | Buy |
118,720
+11,973
| +11% | +$382K | 1.06% | 28 |
|
|
2016
Q1 | $3M | Sell |
106,747
-11,882
| -10% | -$339K | 0.9% | 34 |
|
|
2015
Q4 | $3.63M | Buy |
118,629
+8,459
| +8% | +$266K | 1.05% | 31 |
|
|
2015
Q3 | $3.28M | Sell |
110,170
-8,467
| -7% | -$271K | 0.91% | 37 |
|
|
2015
Q2 | $3.77M | Sell |
118,637
-4,048
| -3% | -$132K | 0.89% | 35 |
|
|
2015
Q1 | $4.05M | Buy |
122,685
+3,438
| +3% | +$109K | 0.96% | 32 |
|
|
2014
Q4 | $3.52M | Sell |
119,247
-4,756
| -4% | -$136K | 0.84% | 36 |
|
|
2014
Q3 | $3.48M | Buy |
124,003
+170
| +0.1% | +$4.77K | 0.82% | 36 |
|
|
2014
Q2 | $3.49M | Sell |
123,833
-795
| -0.6% | -$22.7K | 0.82% | 36 |
|
|
2014
Q1 | $3.8M | Sell |
124,628
-1,866
| -1% | -$55.6K | 0.92% | 32 |
|
|
2013
Q4 | $3.68K | Sell |
126,494
-3,004
| -2% | -$87.4K | 0.96% | 31 |
|
|
2013
Q3 | $3.53M | Buy |
129,498
+1,236
| +1% | +$33.6K | 0.99% | 30 |
|
|
2013
Q2 | $3.41M | Buy |
+128,262
| New | +$3.54M | 0.98% | 32 |
|
Other funds holding PFE
M&R Capital Management's PFE Position: Q3 2024 in Review
M&R Capital Management reduced its Pfizer (PFE) stake by 2.2% in Q3 2024, selling an estimated $21.5K and leaving 32,296 shares worth $935K. The position accounts for 0.21% of the portfolio, ranked #64.
M&R Capital Management first reported a position in PFE in Q2 2013 and has held it in 46 quarters since. The position peaked at $5.39M in Q2 2019. 2,910 funds tracked by Wall St. Rank hold PFE as of Q3 2024.
- M&R Capital Management held 32,296 shares of Pfizer worth $935K as of Q3 2024.
- M&R Capital Management sold 737 Pfizer shares in Q3 2024, an estimated $21.5K.
- Pfizer made up 0.21% of M&R Capital Management's portfolio in Q3 2024, its #64 holding.
- M&R Capital Management first reported a position in Pfizer in Q2 2013 and has held it in 46 quarters since.
- M&R Capital Management's Pfizer position peaked at $5.39M in Q2 2019.
- 2,910 funds tracked by Wall St. Rank held Pfizer as of Q3 2024.
Based on M&R Capital Management's 13F filing for Q3 2024, filed 2 Oct 2024.